Nuestros investigadores

Antonio González Martín

Publicaciones científicas más recientes (desde 2010)

Autores: Lorusso, D. , (Autor de correspondencia); Pignata, S. ; González, Antonio José;
ISSN 0923-7534  Vol. 30  Nº 4  2019  págs. 497 - 498
Autores: Suárez, Victor Manuel; et al.
ISSN 1048-891X  Vol. 29  Nº 4  2019  págs. 835 - 839
Autores: Vergote, I., (Autor de correspondencia); Coleman, R. L.; Pignata, S.; et al.
ISSN 0090-8258  Vol. 154  Nº 2  2019  págs. 255 - 258
Autores: Vergote, I. , (Autor de correspondencia); Coleman, R. L. ; Pignata, S.; et al.
ISSN 1048-891X  Vol. 29  Nº 7  2019  págs. 1094 - 1097
Autores: Matulonis, U. A. , (Autor de correspondencia); Shapira-Frommer, R.; Santin, A. D.; et al.
ISSN 0923-7534  Vol. 30  Nº 7  2019  págs. 1080 - 1087
Background Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic cancer-related death in developed countries and new treatments are needed. Previous studies of immune checkpoint blockade showed low objective response rates (ORR) in ROC with no identified predictive biomarker. Patients and methods This phase II study of pembrolizumab (NCT02674061) examined two patient cohorts with ROC: cohort A received one to three prior lines of treatment with a platinum-free interval (PFI) or treatment-free interval (TFI) between 3 and 12months and cohort B received four to six prior lines with a PFI/TFI of >= 3months. Pembrolizumab 200mg was administered intravenously every 3weeks until cancer progression, toxicity, or completion of 2years. Primary end points were ORR by Response Evaluation Criteria in Solid Tumors version 1.1 per blinded independent central review by cohort and by PD-L1 expression measured as combined positive score (CPS). Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results Cohort A enrolled 285 patients; the first 100 served as the training set for PD-L1 biomarker analysis. Cohort B enrolled 91 patients. ORR was 7.4% for cohort A and 9.9% for cohort B. Median DOR was 8.2months for cohort A and not reached for cohort B. DCR was 37.2% and 37.4%, respectively, in cohorts A and B. Based on the training set analysis, CPS 1 and 10 were selected for evaluation in the confirmation set. In the confirmation set, ORR was 4.1% for CPS<1, 5.7% CPS >= 1, and 10.0% for CPS >= 10. PFS was 2.1months for both cohorts. Median OS was not reached for cohort A and was 17.6months for cohort B. Toxicities were consistent with other single-agent pembrolizumab trials. Conclusions Single-agent pembrolizumab showed modest activity in patients with ROC. Higher PD-L1 expression was correlated with higher response. Clinical Trial Number, NCT02674061
Autores: González, Antonio José, (Autor de correspondencia); Oza, A. M. ; Embleton, A. C.; et al.
ISSN 0090-8258  Vol. 152  Nº 1  2019  págs. 53 - 60
Objective. In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (FIT) population. We explored treatment effect according to stage and extent of residual disease. Methods. Patients with stage IIB-IV or high-risk (grade 3/clear-cell) stage 1-IIA ovarian cancer were randomized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7.5 mg/kg every 3 weeks followed by single-agent bevacizumab for 12 further cycles (total duration 12 months). Post hoc exploratory analyses of subgroups defined by stage and extent of residual disease at diagnosis within the stage IIIB-IV population (European indication) was performed. Results. The PFS benefit from bevacizumab was seen consistently in all subgroups explored. The PFS hazard ratio was 0.77 (95% confidence interval [CI], 0.59-0.99) in 411 patients with stage IIIB-IV ovarian cancer with no visible residuum and 0.81 (95% CI, 0.69-0.95) in 749 patients with stage IIIB-IV disease and visible residuum. As in the ITT population, no OS difference was detected in any subgroup except the previously described 'high-risk' subgroup. Safety results in analyzed subgroups were consistent with the overall population. Conclusions. Adding bevacizumab to front-line chemotherapy improves PFS irrespective of stage/residual disease. In patients with stage III with >1 cm residuum, stage IV or inoperable disease, this translates into an OS benefit. No OS benefit or detriment was seen in other subgroups explored. (C) 2018 The Authors. Published by Elsevier Inc.
Autores: Garcia, Y. G., (Autor de correspondencia); Ferre, A. D.; Mendiola, C.; et al.
ISSN 1048-891X  Vol. 29  Nº 6  2019  págs. 1050 - 1056
Background Bevacizumab is an approved treatment after primary debulking surgery for ovarian cancer. However, there is limited information on bevacizumab added to neoadjuvant chemotherapy before interval debulking surgery. Objective To evaluate neoadjuvant bevacizumab in a randomized phase II trial. Methods Patients with newly diagnosed stage III/IV high-grade serous/endometrioid ovarian cancer were randomized to receive four cycles of neoadjuvant chemotherapy with or without >= 3 cycles of bevacizumab 15 mg/kg every 3 weeks. After interval debulking surgery, all patients received post-operative chemotherapy (three cycles) and bevacizumab for 15 months. The primary end point was complete macroscopic response rate at interval debulking surgery. Results Of 68 patients randomized, 64 completed four neoadjuvant cycles; 22 of 33 (67%) in the chemotherapy-alone arm and 31 of 35 (89%) in the bevacizumab arm (p=0.029) underwent surgery. The complete macroscopic response rate did not differ between treatment arms in either the intention-to-treat population of 68 patients (6.1% vs 5.7%, respectively; p=0.25) or the 55 patients who underwent surgery (8.3% vs 6.5%; p=1.00). There was no difference in complete cytoreduction rate or progression-free survival between the treatment arms. During neoadjuvant therapy, grade >= 3 adverse events were more common with chemotherapy alone than with bevacizumab (61% vs 29%, respectively; p=0.008). Intestinal (sub)occlusion, fatigue/asthenia, abdominal infection, and thrombocytopenia were less frequent with bevacizumab. The incidence of grade >= 3 adverse events was 9% in the control arm versus 16% in the experimental arm in the month after surgery. Conclusions Adding three to four pre-operative cycles of bevacizumab to neoadjuvant chemotherapy for unresectable disease did not improve the complete macroscopic response rate or surgical outcome, but improved surgical operability without increasing toxicity. These results support the early integration of bevacizumab in carefully selected high-risk patients requiring neoadjuvant chemotherapy for initially unresectable ovarian cancer.
Autores: Colombo, N., (Autor de correspondencia); Sessa, C.; du Bois, A.; et al.
ISSN 1048-891X  Vol. 29  Nº 4  2019  págs. 728 - 760
The development of guidelines recommendations is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients with cancer across Europe. ESMO and ESGO jointly developed clinically relevant and evidence-based recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer. The ESMO-ESGO consensus conference on ovarian cancer was held on April 12-14, 2018 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five clinically relevant questions regarding ovarian cancer relating to each of the following four areas: pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurrent disease. Relevant scientific literature, as identified using a systematic search, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. The recommendations presented here are thus based on the best available evidence and expert agreement. This article presents the recommendations of this ESMO-ESGO consensus conference, together with a summary of evidence supporting each recommendation.
Autores: Lee, C. K., (Autor de correspondencia); Asher, R.; Friedlander, M. ; et al.
ISSN 0959-8049  Vol. 117  2019  págs. 99 - 106
Background: Platinum-resistant ovarian cancer (PROC) is associated with a variable prognosis and unpredictable survival times. We have developed and validated a prognostic nomogram with the objective of improving the prediction of overall survival (OS) in patients treated with chemotherapy. Methods: The nomogram was developed using data from a training cohort of patients from two trials, including the chemotherapy-only arm in AURELIA and all randomised patients in CARTAXHY. Multivariable proportional hazards models were generated based on pretreatment characteristics to develop a nomogram that classifies patients based on OS. We subsequently assessed the performance of the nomogram in terms of discrimination and calibration in independent validation patient cohorts: PENELOPE and the bevacizumab-chemotherapy arm of AURELIA. Results: The nomogram included six significant OS predictors, in order of importance: performance status, ascites, size of the largest tumour, CA-125, platinum-free interval and primary platinum resistance (C-statistic 0.69). In the training cohort, the median OS in the good, intermediate and poor prognosis groups was 25.3, 15.2 and 7.4 months, respectively. In the PENELOPE validation cohort (C-statistic 0.59), the median OS in the good, intermediate and poor prognosis groups was 18.5, 10.3 and 5.8 months, respectively. In the AURELIA bevacizumab-chemotherapy validation cohort (C-statistic 0.67), the median OS in good, intermediate and poor prognosis groups was 26.7, 13.8 and 10.0 months, respectively. Conclusions: This nomogram with six pretreatment characteristics allows prediction of OS in PROC and could be used for stratification of patients in clinical trials as well as for counselling patients about prognosis. (C) 2019 Published by Elsevier Ltd.
Autores: O'Malley, D. M.; Matulonis, U. A.; Birrer, M. J. ; et al.
ISSN 0732-183X  Vol. 37  Nº 15, Suppl. S  2019  págs. 5520
Autores: Fotopoulou, C. , (Autor de correspondencia); Sehouli, J.; Mahner, S.; et al.
ISSN 0923-7534  Vol. 29  Nº 8  2018  págs. 1610 - 1613
Autores: Harter, P., (Autor de correspondencia); du Bois, A.; Sehouli, J. ; et al.
ISSN 0932-0067  Vol. 298  Nº 5  2018  págs. 859 - 860
Hyperthermic intraperitoneal chemotherapy (HIPEC) is promoted by some as a standard treatment for peritoneal carcinomatosis of epithelial ovarian cancer (EOC) and other tumor entities, despite lack of robust data supporting this. Publicly available evidence addressing the value of HIPEC in EOC is rather inconclusive, revealing contradictory and inconsistent results while some studies even report harm to the patients from a higher morbidity. On this ground, we cannot recommend the implementation and use of HIPEC outside of a randomized clinical trial setting.
Autores: Oaknin, A.; Guarch, R.; Barretina, P.; et al.
ISSN 1699-048X  Vol. 20  Nº 3  2018  págs. 424
Because of advances in the understanding of histological and molecular characteristics in ovarian cancer, it is now possible to recognize the existence of five subtypes, which in turn has allowed a more refined therapeutic approach and better design of clinical trials. Each of these five subtypes has specific histological features and a particular biomarker expression, as well as mutations in different genes, some of which have prognostic and predictive value. CA125 and HE4 are examples of ovarian cancer biomarkers used in the diagnosis and follow-up of these malignancies. Currently, somatic or germinal mutations on BRCA1 and BRCA2 genes are the most important biomarkers in epithelial ovarian cancer having prognostic and predictive value. This article will review the histological and molecular characteristics of the five subtypes of ovarian cancer, describing the most important biomarkers and mutations that can guide in diagnosis, screening and tailored treatment strategy.
Autores: Santaballa, A., (Autor de correspondencia); Matias-Guiu, X.; Redondo, A.; et al.
ISSN 1699-048X  Vol. 20  Nº 1  2018  págs. 29 - 37
Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defined and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge of the molecular abnormalities in EC have permitted the development of promising targeted therapies.
Autores: Oaknin, A.; Guarch, R.; Barretina, P.; et al.
ISSN 1699-8855  Vol. 51  Nº 2  2018  págs. 84-96
Advances in the understanding of the histological and molecular characteristics of ovarian cancer now allow 5subtypes to be identified, leading to a more refined therapeutic approach and improved clinical trials. Each of the subtypes has specific histological features and a particular biomarker expression, as well as mutations in different genes, some of which have prognostic and predictive value. CA125 and HE4 are examples of ovarian cancer biomarkers used in diagnosis and follow-up. Currently, somatic or germinal mutations on BRCA1 and BRCA2 genes are the most important biomarkers in epithelial ovarian cancer, having prognostic and predictive value. In this article, a group of experts from the Spanish Society of Medical Oncology and the Spanish Society of Pathology review the histological and molecular characteristics of the 5subtypes of ovarian cancer and describe the most useful biomarkers and mutations for diagnosis, screening and tailored treatment strategy.
Autores: Provencher, DM.; Gallagher, CJ.; Parulekar, WR.; et al.
ISSN 0923-7534  Vol. 29  Nº 2  2018  págs. 431-438
BACKGROUND: The purpose of this multistage, adaptively, designed randomized phase II study was to evaluate the role of intraperitoneal (i.p.) chemotherapy following neoadjuvant chemotherapy (NACT) and optimal debulking surgery in women with epithelial ovarian cancer (EOC). PATIENTS AND METHODS: We carried out a multicenter, two-stage, phase II trial. Eligible patients with stage IIB-IVA EOC treated with platinum-based intravenous (i.v.) NACT followed by optimal (<1¿cm) debulking surgery were randomized to one of the three treatment arms: (i) i.v. carboplatin/paclitaxel, (ii) i.p. cisplatin plus i.v./i.p. paclitaxel, or (iii) i.p. carboplatin plus i.v./i.p. paclitaxel. The primary end point was 9-month progressive disease rate (PD9). Secondary end points included progression-free survival (PFS), overall survival (OS), toxicity, and quality of life (QOL). RESULTS: Between 2009 and 2015, 275 patients were randomized; i.p. cisplatin containing arm did not progress beyond the first stage of the study after failing to meet the pre-set superiority rule. The final analysis compared i.v. carboplatin/paclitaxel (n¿=¿101) with i.p. carboplatin, i.v./i.p. paclitaxel (n¿=¿102). The intention to treat PD9 was lower in the i.p. carboplatin arm compared with the i.v. carboplatin arm: 24.5% (95% CI 16.2% to 32.9%) versus 38.6% (95% CI 29.1% to 48.1%) P¿=¿0.065. The study was underpowered to detect differences in PFS: HR PFS 0.82 (95% CI 0.57-1.17); P¿=¿0.27 and OS HR 0.80 (95% CI 0.47-1.35)
Autores: Owonikoko, T. K.; Papadopoulos, K. P.; Gil-Martin, M. ; et al.
ISSN 0923-7534  Vol. 29  Nº Suppl.8  2018 
Autores: González, Antonio José; Mirza, M. R.; Vergote, I.; et al.
ISSN 0923-7534  Vol. 29  Nº Supl. 8  2018 
Autores: Moore, K. N.; Colombo, N.; Scambia, G. ; et al.
ISSN 0923-7534  Vol. 29  Nº Suppl. 9  2018  págs. 727 - 727
Autores: Rischin, D.; Gil-Martin, M.; González, Antonio José; et al.
ISSN 0923-7534  Vol. 29  Nº Suppl. 10  2018 
Autores: Ledermann, J. A.; Shapira-Frommer, R. ; Santin, A.; et al.
ISSN 0923-7534  Vol. 29  Nº Suppl.8  2018  págs. 728 - 728
Autores: Gonzalez-Dominguez, A.; Moya, C.; Simon, S.; et al.
ISSN 1098-3015  Vol. 21  Nº Suppl. 3  2018  págs. S47 - S47
Autores: Quintela-Fandino, Miguel; Soberon, Nora; Lluch, Ana; et al.
ISSN 1949-2553  Vol. 8  Nº 13  2017  págs. 21472-21482
Cumulative toxicity from weekly paclitaxel (myalgia, peripheral neuropathy, fatigue) compromises long-term administration. Preclinical data suggest that the burden of critically short telomeres (< 3 kilobases, CSTs), but not average telomere length by itself, accounts for limited tissue renewal and turnover capacity. The impact of this parameter (which can be modified with different therapies) in chemotherapy-derived toxicity has not been studied.Blood from 115 treatment-naive patients from a clinical trial in early HER2-negative breast cancer that received weekly paclitaxel (80 mg/m2 for 12 weeks) either alone or in combination with nintedanib and from 85 healthy controls was prospectively obtained and individual CSTs and average telomere lenght were determined by HT Q-FISH (high-throughput quantitative FISH). Toxicity was graded according to NCI common toxicity criteria for adverse events (NCI CTCAE V.4.0). The variable under study was "number of toxic episodes" during the 12 weeks of therapy.The percentage of CSTs ranged from 6.5%-49.4% and was directly associated with the number of toxic events (R2 = 0.333; P < 0.001). According to a linear regression model, each 18% increase in the percentage of CSTs was associated to one additional toxic episode during the paclitaxel cycles; this effect was independent of the age or treatment arm. Patients in the upper quartile (> 21.9% CSTs) had 2-fold higher number of neuropathy (P = 0.04) or fatigue (P = 0.019) episodes and >3-fold h
Autores: Oza, Amit M.; Selle, Frederic; Davidenko, Irina; et al.
ISSN 1525-1438  Vol. 27  Nº 1  2017  págs. 50-58
Extended bevacizumab demonstrated increased incidences of proteinuria and hypertension compared with 12 or 15 months of bevacizumab in previous trials, but these rarely led to bevacizumab discontinuation. Median PFS is the longest reported for frontline bevacizumab-containing therapy. The longer bevacizumab duration beyond 15 months in this study may improve PFS without substantially compromising safety.
Autores: Poveda, A; Del Campo, J M; Ray-Coquard, I; et al.
ISSN 1569-8041  Vol. 28  Nº 6  2017  págs. 1280-87
PM01183 is an active drug in platinum-resistant/refractory ovarian cancer and warrants further development. The highest activity was observed in platinum-resistant disease. Its safety profile indicates the dose should be adjusted to body surface area (mg/m2).
Autores: González, Antonio José; Lluch, A.; Aba, E.; et al.
ISSN 1699-3055  Vol. 19  Nº 5  2017  págs. 616-624
High tumor burden, time to recurrence after prior therapy and having a triple-negative phenotype were the prognostic factors for which the greatest consensus was found for identifying patients with aggressive HER2-negative mBC. Identifying patients with aggressive disease leads to different therapeutic approaches.
Autores: Sorio, Roberto; Roemer-Becuwe, Celia; Hilpert, Felix; et al.
ISSN 1095-6859  Vol. 144  Nº 1  2017  págs. 65-71
In exploratory analyses, PFS and response rate improvement with bevacizumab were consistent in older and younger patients. Grade¿3 hypertension was more common in elderly bevacizumab-treated patients; careful monitoring is recommended. Overall, bevacizumab-containing therapy was well tolerated in a selected population aged ¿65years, suggesting a favourable benefit:risk profile. However, geriatric assessments are needed to improve selection of elderly patients potentially gaining symptom and quality of life improvements from bevacizumab-containing therapy
Autores: Quintela-Fandino, Miguel; Lluch, Ana; Manso, Luis; et al.
ISSN 1557-3265  Vol. 23  Nº 6  2017  págs. 1432-1441
Baseline hypoxic tumors (measured with 18F-FMISO-PET do not benefit from neoadjuvant nintedanib.
Autores: González, Antonio José;
ISSN 1474-5488  Vol. 18  Nº 1  2017  págs. 8-9
Autores: Ledermann, Jonathan A.; Embleton, Andrew C.; Raja, Fharat; et al.
Revista: LANCET
ISSN 1474-547X  Vol. 387  Nº 10023  2016  págs. 1066-1074
Cediranib, when given orally with chemotherapy and continued as maintenance, yielded a meaningful improvement [corrected] in progression-free survival in women with recurrent platinum-sensitive ovarian cancer, albeit with added toxic effects. The positive results in ICON6 could provide women with a new therapeutic option for recurrent ovarian cancer. Assessment of the secondary endpoint of overall survival will need longer follow-up.
Autores: Kurzeder, Christian; Bover, Isabel; Marme, Frederik; et al.
ISSN 1527-7755  Vol. 34  Nº 21  2016  págs. 2516-25
Autores: Colombo, N.; Creutzberg, C.; Amant, F.; et al.
ISSN 1569-8041  Vol. 27  Nº 1  2016  págs. 16-41
Autores: Hergueta-Redondo, Marta; Sarrio, David; Molina-Crespo, Angela; et al.
ISSN 1949-2553  Vol. 7  Nº 35  2016  págs. 56295-56308
Importantly, GSDMB expression promotes survival to trastuzumab in different HER2-positive breast carcinoma cells, and is associated with trastuzumab resistance phenotype in vivo in Patient Derived Xenografts. In summary, our data identifies the ERBB2 co-amplified and co-expressed gene GSDMB as a critical determinant of poor prognosis and therapeutic response in HER2-positive breast cancer.
Autores: Kim, Sung-Bae; Wildiers, Hans; Krop, Ian E.; et al.
ISSN 1097-0215  Vol. 139  Nº 10  2016  págs. 2336-2342
Consistent with other reports, benefit was seen with T-DM1 regardless of PIK3CA mutation status. In a multivariate analysis including an interaction term (treatment group by log2-transformed HER2 mRNA), patients with higher HER2 mRNA levels benefited more from receiving T-DM1 (HR, 0.84; 95% CI, 0.75-0.94; interaction p value¿=¿0.0027). In summary, T-DM1 prolonged median PFS in all biomarker subgroups analyzed, including activating PIK3CA mutations, with numerically greater benefit in patients with tumors expressing HER2 mRNA >median vs. ¿median.
Autores: Maria del Campo, Josep; Birrer, Michael; Davis, Craig; et al.
ISSN 1095-6859  Vol. 142  Nº 1  2016  págs. 62-69
Gedatolisib administered by weekly intravenous infusion demonstrated acceptable tolerability and moderate activity in patients with recurrent endometrial cancer. PF-04691502 daily oral dosing was not well tolerated. Clinical benefit response criteria for proceeding to stage 2 were only met in the gedatolisib/stathmin-low arm. Stathmin-high expression did not correlate with greater treatment efficacy. registration ID: NCT01420081
Autores: González, Antonio José; Alba, Emilio; Ciruelos, Eva; et al.
ISSN 1873-5576  Vol. 16  Nº 5  2016  págs. 415-428
Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane
Autores: González, Antonio José; Pautier, Patricia; Mahner, Sven; et al.
ISSN 1525-1438  Vol. 26  Nº 5  2016  págs. 898-905
Based on part 1 tolerability, the Independent Data Monitoring Committee had no objection to PENELOPE proceeding to part 2, a double-blind randomized comparison of chemotherapy (topotecan, paclitaxel, or gemcitabine) plus pertuzumab or placebo.
Autores: Mirza, M. R.; Monk, B. J.; Herrstedt, J.; et al.
ISSN 1533-4406  Vol. 375  Nº 22  2016  págs. 2154-2164
Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded by Tesaro; number, NCT01847274 .
Autores: Santaballa, A.; Barretina, P.; Casado, A.; et al.
ISSN 1699-3055  Vol. 18  Nº 12  2016  págs. 1206-1212
Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer (OC) is the first cause of death due to gynecological cancer and the fifth cause of death for cancer in women in Spain. The aim of this guideline is to summarize the current evidence and to give evidence-based recommendations for clinical practice.
Autores: Vergote, Ignace; Banerjee, Susana; Gerdes, Anne-Marie; et al.
ISSN 1879-0852  Vol. 69  2016  págs. 127-134
Autores: Vrdoljak, E.; Marschner, N.; Zielinski, C.; et al.
ISSN 1569-8041  Vol. 27  Nº 11  2016  págs. 2046-2052
In this trial, continuing bevacizumab beyond first and second progression of LR/mBC improved second-line PFS, but no improvement in longer term efficacy was observed. The second-line PFS benefit appears to be achieved without detrimentally affecting quality of life.
Autores: Sehouli, J.; Chekerov, R.; Reinthaller, A.; et al.
ISSN 1569-8041  Vol. 27  Nº 12  2016  págs. 2236-2241
The combination of carboplatin and topotecan was well tolerated with significant lower rates of severe hematological toxicities but did not improve PFS or OS in platinum-sensitive relapsed ovarian cancer compared with established standard regimens.
Autores: Chiva, Luis; et al.
ISSN 1534-4681  Vol. 23  Nº 5  2016  págs. 1666-1673
Complete cytoreduction after IDS yields a inferior outcome in terms of median survival than PDS of almost 2 years. Despite the higher rate of complete resection, IDS apparently fails to improve the results obtained by primary debulking.
Autores: Freyer, Gilles; Ray-Coquard, Isabelle; Fischer, Dorothea; et al.
ISSN 1525-1438  Vol. 26  Nº 2  2016  págs. 240-247
Partially platinum-sensitive patients with recurrent ovarian carcinoma who received platinum-based therapy had improved outcomes compared with those who did not. No clear demographic criteria for choosing platinum- versus nonplatinum-based therapy for PPS patients were identified from patient records.
Autores: Bellet, Meritxell; Gray, Kathryn P.; Francis, Prudence A.; et al.
ISSN 1527-7755  Vol. 34  Nº 14  2016  págs. 1584-93
During the first year, most patients on exemestane plus triptorelin had E2 levels below the defined threshold of 2.72 pg/mL, consistent with levels reported in postmenopausal patients on aromatase inhibitors, but at each time point, at least 17% of patients had levels greater than the threshold.
Autores: Colombo, Nicoletta; Creutzberg, Carien; Amant, Frederic; et al.
ISSN 0167-8140  Vol. 117  Nº 3  2015  págs. 559-581
Autores: Martin, Miguel; Gonzalez-Rivera, Milagros; Morales, Serafin; et al.
ISSN 1473-4877  Vol. 31  Nº 6  2015  págs. 1129-1137
Though this study does not include evaluation of the impact of GEP on long-term outcomes, it was found that GEP results influenced the treatment decisions of medical oncologists and their confidence in adjuvant therapy selection. Patients' anxiety about the selected adjuvant therapy decreased with use of the GEP.
Autores: Mota, Alba; Carlos Trivino, Juan; Rojo-Sebastian, Alejandro; et al.
ISSN 1471-2407  Vol. 15  2015  págs. 940
Altogether, our results shed light on the clonal evolution of the distinct tumor regions identifying the most aggressive subpopulations and at least some of the genes that may be implicated in its progression and recurrence, and highlights the importance of considering intra-tumor heterogeneity when carrying out genetic and genomic studies, especially when these are aimed to diagnostic procedures or to uncover possible therapeutic strategies
Autores: Oaknin, A.; Rubio, M. J.; Redondo, A.; et al.
ISSN 1699-3055  Vol. 17  Nº 12  2015  págs. 1036-1042
Cervical cancer (CC) is the second most common cancer worldwide, strongly linked to high-risk human papilloma virus infection. Although screening programs have led to a relevant reduction in the incidence and mortality due to CC in developed countries, it is still an important cause of mortality in undeveloped countries. Clinical stage is still the most relevant prognostic factor. In early stages, the primary treatment is surgery or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. In the setting of recurrent or metastatic CC, for the first time ever, the combination of chemotherapy plus bevacizumab prolongs the overall survival beyond 12 months. Therefore, this regimen is considered by most of the oncologist a new standard of care for metastatic/recurrent CC
Autores: González, Antonio José; Bover, I.; del Campo, J. M.; et al.
ISSN 1699-3055  Vol. 16  Nº 12  2014  págs. 1067-1071
Ovarian cancer is the leading cause of death due to gynecological cancer and the 5th cause of death for cancer in women in Europe. Optimal management of patients with ovarian cancer needs the participation of a well-trained multidisciplinary team. In the last few years, we have observed a significant improvement in the knowledge of the molecular biology of the different histotypes of ovarian cancer that will probably change our standard of care in the forthcoming years. In this Guideline, we summarize the most current evidence for the medical management of ovarian cancer
Autores: Quintela-Fandino, Miguel; Bueno, Maria J.; Lombardia, Luis; et al.
ISSN 1878-0261  Vol. 8  Nº 8  2014  págs. 1719-1728
Level 1B was the RP2D as it provided adequate pharmacodynamic exposure to dovitinib. The G2071A germline variant act as a genetic modifier that renders different tumors sensitive to dovitinib.
Autores: Krop, Ian E.; Kim, Sung-Bae; González, Antonio José; et al.
ISSN 1474-5488  Vol. 15  Nº 7  2014  págs. 689-699
Trastuzumab emtansine should be considered as a new standard for patients with HER2-positive advanced breast cancer who have previously received trastuzumab and lapatinib.
Autores: Peiró V.; Chiva, Luis; González, Antonio José; et al.
ISSN 2253-654X  Vol. 33  Nº 2  2014  págs. 87-92
PET/CT is postulated as a useful imaging test for the management of vulvar cancer, mainly in the identification of nodal metastases. It may affect both surgical planning and clinical management. Larger series are needed to confirm our findings.
Autores: Quintela-Fandino, M.; Urruticoechea, A.; Guerra, J.; et al.
ISSN 1532-1827  Vol. 111  Nº 6  2014  págs. 1060-1064
The combination allows the delivery of full-dose intensity, while efficacy seems promising.
Autores: Steegmann, J. L.; Sanchez Torres, J. M.; Colomer, R.; et al.
ISSN 1699-048X  Vol. 15  Nº 6  2013  págs. 477-483
In Spanish hospitals, about half of patients with non-myeloid malignancies undergoing systemic therapy fulfilled anaemia criteria (87 % mild). Approximately two-third of patients with anaemia do not receive specific treatment and ESA use is below current guidelines.
Autores: González, Antonio José; Redondo, A.; Jurado, M.; et al.
ISSN 1699-048X  Vol. 15  Nº 7  2013  págs. 509-525
In 2006, under the auspices of The Spanish Research Group for Ovarian Cancer (Spanish initials GEICO), the first "Treatment Guidelines in Ovarian Cancer" were developed and then published in Clinical and Translational Oncology by Poveda Velasco et al. (Clin Transl Oncol 9(5):308-316, 2007). Almost 6 years have elapsed and over this time, we have seen some important developments in the treatment of ovarian cancer. Significant changes were also introduced after the GCIG-sponsored 4th Consensus Conference on Ovarian Cancer by Stuart et al. (Int J Gynecol Cancer 21:750-755, 2011). So we decided to update the treatment guidelines in ovarian cancer and, with this objective, a group of investigators of the GEICO group met in February 2012. This study summarizes the presentations, discussions and evidence that were reviewed during the meeting and during further discussions of the manuscript.
Autores: Ledermann, J. A.; Raja, F. A.; Fotopoulou, C.; et al.
ISSN 0923-7534  Vol. 24  Nº Suppl.6  2013  págs. i24-32
Autores: González, Antonio José; Gladieff, Laurence; Tholander, Bengt; et al.
ISSN 1879-0852  Vol. 49  Nº 18  2013  págs. 3831-3838
OCTAVIA met its primary objective, demonstrating median PFS of approximately 2 years. This bevacizumab-containing regimen is active and tolerable.
Autores: Raja, F. A.; Counsell, N.; Colombo, N.; et al.
ISSN 1569-8041  Vol. 24  Nº 12  2013  págs. 3028-3034
In this individual patient data (IPD) meta-analysis, we have demonstrated that combination-platinum chemotherapy improves OS and PFS across all subgroups. This provides the strongest evidence to date of the benefit of combination-platinum over single-agent platinum.
Autores: Pritchard, Kathleen I.; Burris, Howard A., III; Ito, Yoshinori; et al.
ISSN 1938-0666  Vol. 13  Nº 6  2013  págs. 421-432
Autores: González, Antonio José;
ISSN 1569-8041  Vol. 24  Nº Supl. 10  2013  págs. 48-52
Approximately 75% of patients with advanced ovarian cancer will have a recurrence of their disease within the first 3 years after upfront surgery and paclitaxel-carboplatin-based chemotherapy. An optimal choice of treatment of patients with a recurrence is an important issue, and several factors should be taken into account in this decision-making, including disease, patients, and treatment. Fortunately, we have several strategies that can be of help not only with respect to palliation, but also in terms of survival benefit. Apart from surgery, which will be reviewed in another article of this series, different single cytotoxic agents and combinations and, more recently, the addition of antiangiogenic agents have shown that they can have impact on progression-free survival and, for some strategies, on the overall survival in such patients. In this review, we present an update of the clinical trials that have led to these achievements
Autores: González, Antonio José;
ISSN 1744-8301  Vol. 9  Nº 12 Suppl.  2013  págs. 29-35
Ovarian carcinoma is still one of the most common causes of death from cancer in the western world. Despite high sensitivity to chemotherapy, the majority of patients will relapse within 3 years. In this article the focus is centered on patients who have a late relapse (>12 months). Carboplatin-based regimens are the backbone of treatment for this group, producing clinical benefit with higher rates for progression-free and overall survival. However, not all patients can continue with platinum owing to loss of activity or toxicity (hypersensitivity, neurotoxicity and ototoxicity). In particular, hypersensitivity reactions to carboplatin are a concern and have been reported in approximately 15-20% of women receiving the drug. When expectations for a positive outcome with carboplatin are good, desensitization protocols may be useful so as to continue treatment. If platinum-based regimens are not possible then alternative forms of treatment are required; additional research efforts are being directed towards the development of nonplatinum-based therapies. Promising results have been obtained with the combination of trabectedin plus pegylated liposomal doxorubicin, providing encouragement that it will be a viable option for patients with recurrent ovarian cancer who cannot be treated with a platinum-based chemotherapeutic option
Autores: Cortes, J.; Calvo, V.; Ramirez-Merino, N.; et al.
ISSN 0923-7534  Vol. 23  Nº 5  2012  págs. 1130-1137
Bevacizumab did increase the risk of LVD and hemorrhagic events. The addition of bevacizumab to chemotherapy in patients with metastatic breast cancer was not associated with a significant increase in grade ¿ 3 arterial or venous thromboembolic events, GI perforation, or fatal events.
Autores: Albanell, J.; González, Antonio José; Ruiz-Borrego, M.; et al.
ISSN 0923-7534  Vol. 23  Nº 3  2012  págs. 625-631
Results from the first prospective European study are consistent with published experience and use of the RS as proposed in European clinical practice guidelines and provide evidence on how Oncotype DX and clinicopathological factors are complementary and patient selection may be improved.
Autores: Garcia-Martinez, Elena; Egea Prefasi, Lucas; Garcia-Donas, Jesus; et al.
ISSN 1699-048X  Vol. 13  Nº 5  2011  págs. 307-314
Uterine sarcomas comprise a heterogeneous group of diseases with different pathology appearance, clinical course and natural history. They account for only 3% of all uterine malignancies. The rarity of this entity has precluded the development of large and well designed randomised clinical trials, and for this reason the current management of some aspects of this disease is based on trials or retrospective studies with a low level of evidence. For this reason, it is mandatory to develop international cooperation to carry out clinically relevant clinical trials in this field. Accordingly, based on the relative rarity of these tumours, management of these patients should be centralised and must be performed by a multidisciplinary team including gynaecologic oncologist, pathologist, medical oncologist and radiation oncologist. This review focuses on the most accepted evidence about the management of uterine sarcomas. Although carcinosarcoma has been recently excluded from the sarcoma classification, some aspects of its treatment have also been included in this review.
Autores: Oaknin, Ana; Roda, Desamparado; González, Antonio José; et al.
ISSN 1048-891X  Vol. 21  Nº 6  2011  págs. 1048-1055
The GEICO outpatient modified regimen resulted in a lesser toxicity and a greater rate of treatment completion than previously reported. The accurate selection of patients and the administration following well-defined guidelines can increase the feasibility of IP chemotherapy administration.
Autores: Quintela-Fandino, Miguel; González, Antonio José; Colomer, Ramon;
ISSN 1699-048X  Vol. 12  Nº 10  2010  págs. 662-669
Autores: González, Antonio José; Toledo G,; Chiva, Luis;
ISSN 1699-048X  Vol. 12  Nº 6  2010  págs. 418-30
Epithelial ovarian carcinoma is still the most common cause of death from gynaecological cancer in USA and western Europe. The optimal therapy of epithelial ovarian carcinoma requires participation of a multidisciplinary team - from diagnosis through the entire natural history of each individual patient. Only 20-30% of patients are diagnosed at the initial stage, when appropriate staging surgery in combination with adjuvant chemotherapy for high-risk patients can be curative. Treating patients with advanced disease consists of a staging surgery with maximum cytoreductive effort, followed by chemotherapy with a combination of taxane and carboplatin. Unfortunately, the majority of patients with advanced disease will relapse and become candidates for therapy that comprises individualised chemotherapy, and surgery in selected cases. For this reason, there is still a need for new treatments and strategies in the first-line setting.
Autores: González, Antonio José; de la Cruz, Susana; Marquez, Raul;
ISSN 0167-6806  Vol. 123  Nº Suppl.1   2010  págs. 43-47